Arvinas (ARVN) vs YD Bio (YDES)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Arvinas (ARVN) has outperformed YD Bio (YDES) over the past year, losing 26.8% versus a loss of 70.5%. Arvinas is the larger company by market cap ($449.7 million vs $419.3 million), about 1.1 times the size, while YD Bio is growing revenue faster (+16.9% vs -0.3%). Arvinas converts more of its revenue into profit, with a net margin of -30.8% versus -1392.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | YDES |
|---|---|---|
| Share price | $6.97 | $5.92 |
| Market cap | $449.71M | $419.32M |
| 1-day change | -2.65% | -12.17% |
| YTD return | -41.23% | -51.44% |
| 1-year return | -26.79% | -70.53% |
| 5-year return | -91.79% | — |
| P/E ratio (TTM) | 26.81 | — |
| EPS (TTM) | $0.26 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $262.60M | $596.82K |
| Revenue growth (YoY) | -0.30% | +16.94% |
| Net income (latest FY) | $-80.80M | $-8.31M |
| Gross margin | — | 28.05% |
| Operating margin | -45.13% | -883.31% |
| Net margin | -30.77% | -1392.61% |
| 52-week high | $14.51 | $22.00 |
| 52-week low | $6.74 | $1.70 |
| Distance from 52-week high | -51.96% | -73.09% |
| Analyst consensus | buy | — |
| Avg. price target upside | +99.86% | — |
| Average volume | 800.32K | 289.85K |
| Shares outstanding | 64.52M | 70.83M |
| Employees | 246 | 13 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARVN has outperformed YDES by 43.7 percentage points over the past year.
- Arvinas is more profitable, keeping -30.8 cents of every revenue dollar as net income versus -1392.6 cents for YD Bio.
- YD Bio grew revenue faster in its latest fiscal year (+16.94% vs -0.30%).
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Healthcare · Biotechnology · 246 employees
About YD Bio
YDES stock →YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma.
Healthcare · Biotechnology · 13 employees
ARVN vs YDES FAQ
Which is bigger, Arvinas or YD Bio?
Arvinas (ARVN) is larger, with a market capitalization of $449.71M compared with $419.32M for YD Bio (YDES).
Which stock has performed better over the past year, ARVN or YDES?
ARVN returned -26.79% over the past 12 months, compared with -70.53% for YDES (price return, excluding dividends). Past performance does not predict future results.
Are Arvinas and YD Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.